Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Article
The Often-Missed Corner of Healthcare That Wall Street Is LovingReported by Nathan Reiff. First Published: 3/29/2026. 
Key Points
- Numerous lab equipment stocks are down in the high-teens so far this year, but seemingly modest sales growth may hide fundamental strengths.
- These companies can present a more secure approach to the healthcare industry than some higher-risk alternatives.
- Still, headwinds including tariff impacts and inflation remain a concern.
- Special Report: Elon Musk already made me a “wealthy man”
The healthcare industry is notoriously volatile—company fortunes can be made or broken by a single product or the result of a clinical trial, and stocks in the sector often produce some of the market's wildest swings. Investors who want exposure to the healthcare space but are wary of that turbulence might adopt a "picks and shovels" approach, focusing on companies that supply essential equipment and services rather than higher-risk pharmaceutical names. Lab equipment stocks are often overlooked, even though some companies in this subindustry rank among the largest in healthcare. With several external forces shaping 2026—shifting subsidies, an aging population, inflation, the growing role of AI, and more—core lab equipment names may be especially attractive. Below are some major players worth a closer look for investors considering the space. A Recent Dip Masks Thermo Fisher's Long-Term Strengths
Copper sits at the center of AI expansion, data center growth, and grid upgrades - but new supply takes 20-plus years to bring online. Washington has already shifted its stance, designating copper a strategic asset.
One small North American copper play has assembled seven properties across proven copper belts, using AI-driven exploration modeling, all under a $1 share price - before this supply-demand gap becomes obvious to the broader market. See the copper story behind AI's infrastructure expansion today
$182-billion life sciences, diagnostics, and analytical instruments company Thermo Fisher Scientific (NYSE: TMO) has struggled in early 2026—shares are down more than 15% year-to-date (YTD), and the company recently entered TradeSmith's red zone for financial health. Much of the weakness appears tied to tariffs and currency volatility, which together shaved more than 100 basis points from margins in 2025. There are nevertheless several bright spots in Thermo Fisher's recent performance. In Q4 2025, revenue of $12.2 billion rose 7% year-over-year (YOY), beating analyst estimates by roughly $250 million. Adjusted earnings per share (EPS) also topped expectations at $6.57. That momentum may reflect a string of product launches in recent months, including the Orbitrap Astral Zoom mass spectrometer and new bioreactor offerings. Ultimately, Thermo Fisher's diversified business model could provide a cushion against external pressure. Even if guidance for 2026 is cautious—revenue is expected to increase 4% to 6%—anticipated improvements to EBITDA margin are a tailwind, and underlying customer demand should remain solid. That may explain why, despite the recent selloff, analysts remain largely bullish: 17 of 19 rate the company a Buy or equivalent, and consensus estimates imply more than 29% upside. Danaher's Business May Be Improving, Even as Guidance Remains ModestDanaher Corp. (NYSE: DHR) is down nearly 20% YTD as the instruments, consumables, and reagents firm finds itself in a position similar to Thermo Fisher's. While 2026 guidance points to modest core revenue growth of 3% to 6% YOY, the latest quarter included a top- and bottom-line beat and $5.3 billion in free cash flow for 2025. Two bright spots for 2026 are Danaher's bioprocessing business, expected to deliver high-single-digit revenue growth driven by strong monoclonal antibody demand, and its diagnostics unit. Diagnostics should benefit from FDA clearances, and equipment orders appear to be improving after a prolonged slump, which could further support sales growth. Analysts are reasonably optimistic, forecasting about 12.3% earnings growth over the next year and roughly 35% potential upside in the share price. That sentiment is reflected in ratings: 19 of 22 analysts rate DHR as a Buy. Agilent's Biocare Purchase Could Be a CatalystAgilent Technologies (NYSE: A) has lagged some peers based on its latest earnings, which showed tepid 4.4% YOY revenue growth and slight misses on both revenue and earnings versus expectations. However, Agilent may have a hidden growth engine in its recent acquisition of Biocare Medical, which strengthens its position in cancer diagnostics. Although Biocare cost nearly $1 billion, the deal should add recurring revenue in a growing, higher-margin area and could help lift Agilent's operating margin, which was 24.6% in the most recent quarter. Despite a decline of roughly 17% YTD, analysts see notable upside for Agilent—about 42% potential—and Wall Street rates the stock a Moderate Buy overall, with 13 of 16 ratings at Buy or similar. |
